Apolipoprotein A1 (ApoA1)
The main protein of HDL, the 'good' cholesterol that removes cholesterol from artery walls. A higher ApoA1 is generally protective against heart disease, and it is often used with ApoB (the atherogenic-particle protein) as a ratio to gauge cardiovascular risk.
What it measures
Apolipoprotein A1 is the principal protein component of HDL (high-density lipoprotein), the 'good' cholesterol. HDL's job is reverse cholesterol transport — collecting excess cholesterol from tissues, including artery walls, and returning it to the liver — and ApoA1 is central to how it does this. Because there is roughly one ApoA1 per HDL-related particle, measuring ApoA1 gives a protein-based read of the protective side of the lipid system, complementing HDL cholesterol. A higher ApoA1 is generally associated with lower cardiovascular risk. Its main practical use is alongside ApoB: the ApoB-to-ApoA1 ratio captures the balance between harmful (atherogenic) and protective particles in a single number, and a higher ratio indicates higher risk. A low ApoA1 accompanies the low-HDL pattern of metabolic syndrome, insulin resistance and diabetes, and some genetic conditions.
What a high value can mean
- A protective lipid profile — a higher ApoA1 generally reflects more HDL and lower cardiovascular risk.
- Some genetic and lifestyle factors — regular exercise, moderate alcohol and certain genetics raise it.
- Pregnancy and oestrogen.
What a low value can mean
- Increased cardiovascular risk — a low ApoA1 mirrors a low HDL.
- Metabolic syndrome, insulin resistance, type 2 diabetes — the low-HDL/high-triglyceride pattern.
- Smoking, obesity, physical inactivity.
- Certain genetic conditions and liver disease.
When to discuss with a doctor
ApoA1 is not usually a stand-alone target; its value is mainly as part of the ApoB-to-ApoA1 ratio, which some clinicians use as an overall measure of cardiovascular risk that balances harmful against protective particles. A low ApoA1, like a low HDL, points to a less favourable profile, often as part of a metabolic-syndrome picture that benefits from addressing weight, activity, smoking and blood sugar. Treatment focuses far more on lowering the harmful particles (ApoB/LDL) than on raising ApoA1 directly, since medicines that raise HDL have not clearly reduced risk. Mediora.AI shows ApoA1 with ApoB, HDL and the rest of the lipid panel so the protective-versus-harmful balance is visible; the risk assessment and treatment belong with your doctor.